<!DOCTYPE html><html class="" lang="en"><head>
<!-- REQUIRED META INFORMATION -->
<meta charset="UTF-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta name="viewport" content="width=device-width, initial-scale=1">

<meta name="DCTERMS:contentOwner" content="TNeville">
<meta name="DCTERMS:contentOffice" content="DCRDP:ODP:OMP">

<meta name="DCTERMS:coder" content="^ORDP Webmaster">
<meta name="DCTERMS:coderOffice" content="DCRDP:ODEPPIN:OPPS">

<meta name="description" content="7.00-Hematological-Adult">
<meta name="DCTERMS:dateCertified" content="2019-11-25">
 
<!-- DOCUMENT TITLE -->
<title>7.00 Hematological Disorders - Adult  | Disability | SSA</title>
 
<!-- STYLES -->
<link rel="stylesheet" href="/framework/css/ssa.firefly.css">

<!-- SCRIPTS -->
<script type="text/javascript" async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-TL5XBDT&amp;gtm=4e5b50"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-5GQXH7Q"></script><script src="/framework/js/ssa.firefly.head.js"></script>


<script>(window.BOOMR_mq=window.BOOMR_mq||[]).push(["addVar",{"rua.upush":"false","rua.cpush":"false","rua.upre":"false","rua.cpre":"false","rua.uprl":"false","rua.cprl":"false","rua.cprf":"false","rua.trans":"","rua.cook":"false","rua.ims":"false","rua.ufprl":"false","rua.cfprl":"false","rua.isuxp":"false","rua.texp":"norulematch","rua.ceh":"false","rua.ueh":"false","rua.ieh.st":"0"}]);</script>
                              <script>!function(e){var n="https://s.go-mpulse.net/boomerang/";if("False"=="True")e.BOOMR_config=e.BOOMR_config||{},e.BOOMR_config.PageParams=e.BOOMR_config.PageParams||{},e.BOOMR_config.PageParams.pci=!0,n="https://s2.go-mpulse.net/boomerang/";if(window.BOOMR_API_key="LERZW-HECFS-R8H4E-23UQ7-ERMQB",function(){function e(){if(!o){var e=document.createElement("script");e.id="boomr-scr-as",e.src=window.BOOMR.url,e.async=!0,i.parentNode.appendChild(e),o=!0}}function t(e){o=!0;var n,t,a,r,d=document,O=window;if(window.BOOMR.snippetMethod=e?"if":"i",t=function(e,n){var t=d.createElement("script");t.id=n||"boomr-if-as",t.src=window.BOOMR.url,BOOMR_lstart=(new Date).getTime(),e=e||d.body,e.appendChild(t)},!window.addEventListener&&window.attachEvent&&navigator.userAgent.match(/MSIE [67]\./))return window.BOOMR.snippetMethod="s",void t(i.parentNode,"boomr-async");a=document.createElement("IFRAME"),a.src="about:blank",a.title="",a.role="presentation",a.loading="eager",r=(a.frameElement||a).style,r.width=0,r.height=0,r.border=0,r.display="none",i.parentNode.appendChild(a);try{O=a.contentWindow,d=O.document.open()}catch(_){n=document.domain,a.src="javascript:var d=document.open();d.domain='"+n+"';void(0);",O=a.contentWindow,d=O.document.open()}if(n)d._boomrl=function(){this.domain=n,t()},d.write("<bo"+"dy onload='document._boomrl();'>");else if(O._boomrl=function(){t()},O.addEventListener)O.addEventListener("load",O._boomrl,!1);else if(O.attachEvent)O.attachEvent("onload",O._boomrl);d.close()}function a(e){window.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!window.BOOMR||!window.BOOMR.version&&!window.BOOMR.snippetExecuted){window.BOOMR=window.BOOMR||{},window.BOOMR.snippetStart=(new Date).getTime(),window.BOOMR.snippetExecuted=!0,window.BOOMR.snippetVersion=12,window.BOOMR.url=n+"LERZW-HECFS-R8H4E-23UQ7-ERMQB";var i=document.currentScript||document.getElementsByTagName("script")[0],o=!1,r=document.createElement("link");if(r.relList&&"function"==typeof r.relList.supports&&r.relList.supports("preload")&&"as"in r)window.BOOMR.snippetMethod="p",r.href=window.BOOMR.url,r.rel="preload",r.as="script",r.addEventListener("load",e),r.addEventListener("error",function(){t(!0)}),setTimeout(function(){if(!o)t(!0)},3e3),BOOMR_lstart=(new Date).getTime(),i.parentNode.appendChild(r);else t(!1);if(window.addEventListener)window.addEventListener("load",a,!1);else if(window.attachEvent)window.attachEvent("onload",a)}}(),"".length>0)if(e&&"performance"in e&&e.performance&&"function"==typeof e.performance.setResourceTimingBufferSize)e.performance.setResourceTimingBufferSize();!function(){if(BOOMR=e.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var n=""=="true"?1:0,t="cookiepresent",a="im6jsaqxzhbro2ioayya-f-21113cab2-clientnsv4-s.akamaihd.net",i="false"=="true"?2:1,o={"ak.v":"39","ak.cp":"1204614","ak.ai":parseInt("728289",10),"ak.ol":"0","ak.cr":20,"ak.ipv":4,"ak.proto":"h3","ak.rid":"ca1671e","ak.r":39734,"ak.a2":n,"ak.m":"dsca","ak.n":"essl","ak.bpcip":"67.60.153.0","ak.cport":57631,"ak.gh":"23.201.194.23","ak.quicv":"0x00000001","ak.tlsv":"tls1.3","ak.0rtt":"","ak.0rtt.ed":"","ak.csrc":"-","ak.acc":"","ak.t":"1762526768","ak.ak":"hOBiQwZUYzCg5VSAfCLimQ==UUPU4HVWNF4LNaXyL6sDa3rAmwzB/NvIodGEtMbdFgyCfyizQpGi6JT7O/JRvvXrA5dWuO36wr1/XgCbjudOIfKn7kxvsSoh8T+MDtCJ8Tr8x9EKrezLLOFMUHqL063UsgWUyPlxJzZfVCRbeXpdEzqfIzGXMkhdn7Jdy5aZzDWx/gb/8wcRTPTcJOytm1YRXv5qeIA45XL9pimXASAFcxrOG2V7E0LBLiq4t96Lpq30qardrHLjGUygCxvzAwJaWsSX28POHnR7cTPJ7Jpgid2rjz3qLMST0RfQnX38DeQEIvwz677Ygp0KAS/+tAFjdXYEymHU8pog3fdmP2KbyezagnGVhdV7H8B3UbFxZxjITede3uUCO26ZSuOT+eggu0xdCfGZP+wXSg9t9+2+qonOsB0OBqDE4wSCKKJaUVQ=","ak.pv":"120","ak.dpoabenc":"","ak.tf":i};if(""!==t)o["ak.ruds"]=t;var r={i:!1,av:function(n){var t="http.initiator";if(n&&(!n[t]||"spa_hard"===n[t]))o["ak.feo"]=void 0!==e.aFeoApplied?1:0,BOOMR.addVar(o)},rv:function(){var e=["ak.bpcip","ak.cport","ak.cr","ak.csrc","ak.gh","ak.ipv","ak.m","ak.n","ak.ol","ak.proto","ak.quicv","ak.tlsv","ak.0rtt","ak.0rtt.ed","ak.r","ak.acc","ak.t","ak.tf"];BOOMR.removeVar(e)}};BOOMR.plugins.AK={akVars:o,akDNSPreFetchDomain:a,init:function(){if(!r.i){var e=BOOMR.subscribe;e("before_beacon",r.av,null,null),e("onbeacon",r.rv,null,null),r.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script><link href="https://s.go-mpulse.net/boomerang/LERZW-HECFS-R8H4E-23UQ7-ERMQB" rel="preload" as="script"><style>@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.ttf) format("truetype");font-weight:300;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.ttf) format("truetype");font-weight:400;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.ttf) format("truetype");font-weight:600;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.ttf) format("truetype");font-weight:700;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.ttf) format("truetype");font-weight:800;font-style:normal;font-display:swap}</style><meta property="og:site_name" content="Social Security"><meta property="og:type" content="website"><meta property="og:url" content="https://www.ssa.gov/disability/professionals/bluebook/7.00-HematologicalDisorders-Adult.htm"><meta property="og:title" content="7.00 Hematological Disorders - Adult | Disability | SSA"><meta property="og:description" content="7.00-Hematological-Adult"><meta property="og:image:url" content="https://www.ssa.gov/themes/custom/ssa_core/logo.svg"><meta property="og:image:secure_url" content="https://www.ssa.gov/themes/custom/ssa_core/logo.svg"><meta property="og:image:alt" content="U.S. Social Security Administration"><meta property="og:locale" content="en_US"><meta property="og:locale:alternate" content="es_ES"><script id="boomr-scr-as" src="https://s.go-mpulse.net/boomerang/LERZW-HECFS-R8H4E-23UQ7-ERMQB" async=""></script></head>

<body style="margin: 0px;">
  <!-- BANNER -->
  <aside class="accessibility" id="accessibility"><a href="#content" id="skip-navigation">Skip to main content</a></aside>
<!-- WCMS SITE ALERT (EMERGENCY) -->
<div class="wsa" aria-label="Site Alert" data-type="emergency">
  <div class="wsag">
    <svg focusable="false" height="26" width="26" viewBox="0 0 20 20" aria-hidden="true">
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,15h-1.7v-1.7h1.7v1.7ZM10.8,11.7h-1.7v-4.9h1.7v4.9Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#1C1D1F" fill-rule="evenodd" stroke-width="0" d="M.8,17.5h18.3L10,1.7.8,17.5ZM10.8,15h-1.7v-1.7h1.7v1.7ZM10.8,11.7h-1.7v-4.9h1.7v4.9h0Z" vector-effect="non-scaling-stroke"></path>
    </svg>
    <div>
      <a href="/myaccount/"><u>Social Security and SSI Payments will Continue during the Government Shutdown.  Visit my Social Security for Online Services.</u></a>
    </div>
  </div>
</div>
<!-- WCMS SITE ALERT (INFORMATION) -->
<div class="wsa" aria-label="Site Alert" data-type="information">
  <div class="wsag">
    <svg focusable="false" height="26" width="26" viewBox="0 0 20 20" aria-hidden="true">
      <path fill="#1C1D1F" fill-rule="evenodd" stroke-width="0" d="M10,1.7C5.4,1.7,1.7,5.4,1.7,10s3.7,8.3,8.3,8.3,8.3-3.7,8.3-8.3S14.6,1.7,10,1.7ZM9.2,7.5v-1.7h1.7v1.7h-1.7ZM9.2,9.2v5h1.7v-5h-1.7Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,7.5h-1.7v-1.7h1.7v1.7Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,14.2h-1.7v-5h1.7v5Z" vector-effect="non-scaling-stroke"></path>
    </svg>
    <div>
      <a href="https://www.ssa.gov/manage-benefits/get-benefit-letter"><u>Get a benefit verification letter.</u></a>
    </div>
  </div>
</div>
<ssa-header class="print-dn"></ssa-header><script src="https://www.ssa.gov/legacy/components/dist/ssa-header.js"></script>
  <!-- MAIN CONTENT -->
  <main class="content" id="content" role="main">
    <!-- TITLE BAR -->
    <section class="bg-ivory-200">
      <!-- WRAPPER -->
      <div class="py2 wrapper">
        <h2 class="fw4 ma0" id="Top">Medical/Professional Relations</h2>
</div>
    </section>

    <!-- WRAPPER -->
    <section class="wrapper">
    
    <!--GRID-->
<div class="grid">
	
<!-- FIRST COLUMN -->
<article class="cell w-100 m-w-100">
	
<!-- BREADCRUMBS -->
<nav class="breadcrumbs fs1" aria-label="Breadcrumbs">
  <ol>
    <li><a href="https://www.ssa.gov">SSA Home</a></li>
	<li><a href="https://www.ssa.gov/disability">Disability</a></li>
	<li><a href="../index.htm">Medical/Professional Relations</a></li>
	<li><a href="index.htm">Disability Evaluation Under Social Security</a></li>
	<li><a href="AdultListings.htm">Listing of Impairments - Adult Listings (Part A)</a></li> 
    <li aria-current="page">7.00 Hematological Disorders - Adult</li>
  </ol>
</nav>
</article><!--END FIRST COLUMN-->

<!-- FIRST COLUMN -->
<article class="cell w-100 m-w-20">


<p class="js-toggle"><a href="AdultListings.htm">Adult Listings (Part A)</a></p>
<p class="js-toggle"><a href="ChildhoodListings.htm">Childhood Listings (Part B)</a></p>
<p class="js-toggle"><a href="general-info.htm">General Information</a></p>
<p class="js-toggle"><a href="evidentiary.htm">Evidentiary Requirements</a></p>
<p class="js-toggle"><a href="listing-impairments.htm">Listing of Impairments (overview) </a></p>

<p class="js-toggle"><a href="revisions-rules.html">Revisions to Rules Regarding the Evaluation of Medical Evidence</a></p>
                          </article><!-- END FIRST COLUMN-->

<!--SECOND COLUMN-->
<article class="cell w-100 m-w-80">

      <h2><span><b> Disability Evaluation Under Social Security<br>
        <br>
        7.00    <strong> Hematological Disorders - Adult</strong> <br>
        &nbsp;</b></span></h2>


                            <!--GRID-->
					<div class="grid">

                         <!--FIRST INNER COLUMN-->
					<article class="cell w-100 m-w-20">

<u><b>Section</b></u><br><br>
      <p align="left">
           <a href="#7_01" title=" 7.01 Category of Impairments, Hemicand Lymphatic System"><b>7.01</b>
              <br>
              Category of<br>
              Impairments,<br>
              Hematological<br>
              Disorders<br>
           </a><br>
              <!--<a href="#7_02"
title=" 7.02Chronicanemia"> <b>7.02</b><br>
              Chronic&nbsp;anemia</a>
              <br><br> -->
 <a href="#7_05" title=" 7.05Sicklecelldiseaseorvariant"> <b>7.05</b><br>
              Hemolytic anemias,<br>
              including sickle<br>
              cell disease,<br>
              thalassemia,<br>
              and their variants</a><br>
              <br>
              <!--<a href="#7_06"
title=" 7.06Chronicthrombocytopenia"><b> 7.06</b><br>
              Chronic<br>
              thrombocytopenia&nbsp;<br>
              (due to any cause)</a><br>
              <br> -->
              <!--<a href="#7_07"
title=" 7.07Hereditarytelangiectasia"><b> 7.07</b><br>
              Hereditary<br>
              telangiectasia</a><br>
              <br> -->
              <a href="#7_08" title=" 7.08Coagulationdefects"><b> 7.08</b><br>
              Disorders of<br>
              thrombosis and<br>
              hemostasis<br></a><br>
              <br>
              <!--<a href="#7_09" title=" 7.09Polycythemiavera"> 
              <b>7.09</b><br>
              Polycythemia<br>
              vera (with <br>
              erythrocytosis,<br>
              splenomegaly,<br>
              andleukocytosis<br>
              or<br>
              thrombocytosis)</a><br>
              <br> -->
              <a href="#7_10" title=" 7.10Myelofibrosis"> <b>7.10</b><br>
              Disorders of<br>
              bone marrow<br>
              failure</a><b><br>
              </b>
              <br>
              <!--<a href="#7_15"
title=" 7.15Chronicgramdocytopenia"><b> 7.15</b><br>
              Chronic<br>
              granulocytopenia<br>
              (due to any<br>
            cause)</a>
              <br> -->
              <br>
              <a href="#7_17" title=" 7.17Aplasticanemiasorhematologicmalignancies"> 
              <b>7.17</b><br>
              Hematological<br>
              disorders treated<br>
              by bone marrow<br>
              or stem cell<br>
              transplantation<br></a><br>
              <a href="#7_18" title="Repeated complications of hematological disorders">
              <b>7.18</b><br>
              Repeated<br>
              complications of<br>
              hematological<br>
              disorders<br></a></p>
              
                            </article><!--END FIRST INNER COLUMN-->

							<!--SECOND inner COLUMN-->
							<article class="cell w-100 m-w-80">
                            
      <p id="7_00"><u><b>7.00 Hematological Disorders</b></u></p>
      <p id="7_00A">A. <u>What hematological disorders do we evaluate under these listings?</u></p>
      <ol>
          <li id="7_00A1">
              We evaluate non-malignant (non-cancerous) hematological disorders, such as hemolytic anemias (<a href="#7_05" title="Section 7.05">7.05</a>), 
              disorders of thrombosis and hemostasis (<a href="#7_08" title="Section 7.08">7.08</a>), and disorders of bone marrow failure (<a href="#7_10" title="Section 7.10">7.10</a>).
    These disorders disrupt the normal development and function of white blood cells, red blood cells, platelets, and clotting-factor proteins (factors).
</li>
          <br>
          <li id="7_00A2">We evaluate malignant (cancerous) hematological disorders, such as lymphoma, leukemia, and multiple myeloma, 
          under the appropriate listings in <a href="13.00-NeoplasticDiseases-Malignant-Adult.htm#13_00" title="13.00 Cancer (Malignant Neoplastic Diseases) Page" target="_blank">13.00</a>,
    except for two lymphomas associated with human immunodeficiency virus (HIV) infection.
    We evaluate primary central nervous system lymphoma associated with HIV infection under <a href="14.00-Immune-Adult.htm#14_11B" title="14.00 Immune System Disorders Page, Section 14.11 - Subsection B" target="_blank">14.11B</a>,
    and primary effusion lymphoma associated with HIV infection under <a href="14.00-Immune-Adult.htm#14_11C" title="14.00 Immune System Disorders Page, Section 14.11 - Subsection C" target="_blank">14.11C</a>.
</li>
      </ol>
      <p align="left" id="7_00B">
          B. <u>What evidence do we need to document that you have a hematological disorder?</u> We need the following evidence to document that you have a hematological disorder:
          </p><ol>
              <li id="7_00B1">A laboratory report of a definitive test that establishes a hematological disorder, signed by a physician; or</li>
              <br>
              <li id="7_00B2">
                  A laboratory report of a definitive test that establishes a hematological disorder
                  that is not signed by a physician and a report from a physician that states you have the disorder; or
              </li>
              <br>
              <li id="7_00B3">
                  When we do not have a laboratory report of a definitive test, a persuasive
                  report from a physician that a diagnosis of your hematological disorder was
                  confirmed by appropriate laboratory analysis or other diagnostic method(s).
                  To be persuasive, this report must state that you had the appropriate definitive
                  laboratory test or tests for diagnosing your disorder and provide the results, or
                  explain how your diagnosis was established by other diagnostic method(s) consistent
                  with the prevailing state of medical knowledge and clinical practice.
              </li>
              <br>
              <li id="7_00B4">
                  We will make every reasonable effort to obtain the results of
                  appropriate laboratory testing you have had. We will not purchase complex,
                  costly, or invasive tests, such as tests of clotting-factor proteins,
                  and bone marrow aspirations.
              </li>
          </ol>
      <p></p>
      <p align="left" id="7_00C">
           C. <u>What are hemolytic anemias, and how do we evaluate them under <a href="#7_05" title="Section 7.05">7.05</a>?</u>
          </p><ol>
              <li id="7_00C1">
                 <u>Hemolytic anemias, both congenital and acquired,</u> are disorders that result
                  in premature destruction of red blood cells (RBCs). Hemolytic disorders include
                  abnormalities of hemoglobin structure (hemoglobinopathies), abnormal RBC enzyme
                  content and function, and RBC membrane (envelope) defects that are congenital or acquired.
                  The diagnosis of hemolytic anemia is based on hemoglobin electrophoresis or analysis of
                  the contents of the RBC (enzymes) and membrane. Examples of congenital hemolytic anemias
                  include sickle cell disease, thalassemia and their variants, and hereditary spherocytosis.
                  Acquired hemolytic anemias may result from autoimmune disease (for example, systemic lupus erythematosus)
                  or mechanical devices (for example, heart valves, intravascular patches).
              </li>
              <br>
              <li id="7_00C2">
                  The hospitalizations in <a href="#7_05B" title="Section 7.05B">7.05B</a> do not all have to be for the same complication of the hemolytic anemia. 
                  They may be for three different complications of the disorder. Examples of complications of hemolytic anemia that may result in
                  hospitalization include osteomyelitis, painful (vaso-occlusive) crisis, pulmonary infections or infarctions, acute chest syndrome, pulmonary hypertension, 
                  chronic heart failure, gallbladder disease, hepatic (liver) failure, renal (kidney) failure, nephrotic syndrome, aplastic crisis, and stroke. 
                  We will count the hours you receive emergency treatment in a comprehensive sickle cell disease center immediately before the hospitalization if this treatment is comparable to the treatment provided in a
                hospital emergency department.
            </li>
              <br>
              <li id="7_00C3">For <a href="#7_05C" title="Section 7.05C">7.05C</a>, we do not require hemoglobin to be measured during a period in which you are free of pain or other symptoms of your disorder. 
                We will accept hemoglobin measurements made while you are experiencing complications of your hemolytic anemia.</li>
              <br>
              <li id="7_00C4"><a href="#7_05D" title="Section 7.05D">7.05D</a> refers to the most serious type of beta thalassemia major in which the bone marrow cannot produce sufficient numbers of normal RBCs 
              to maintain life. The only available treatments for beta thalassemia major are life-long RBC transfusions (sometimes called hypertransfusion) or bone marrow transplantation. 
              For purposes of <a href="#7_05D" title="Section 7.05D">7.05D</a>, 
              we do not consider prophylactic RBC transfusions to prevent strokes or other complications in sickle cell disease and its variants to be of equal significance to life-saving RBC transfusions for beta thalassemia major. 
              However, we will consider the functional limitations associated with prophylactic RBC transfusions and any associated side effects (for example, iron overload) under <a href="#7_18" title="Section 7.18">7.18</a>
              and any affected body system(s).
               We will also evaluate strokes and resulting complications under <a href="11.00-Neurological-Adult.htm#11_00" title="11.00 Neurological Disorders Page, Section 11.00" target="_blank">11.00</a> 
              and <a href="12.00-MentalDisorders-Adult.htm#12_00" title="12.00 Neurological Disorders Page, Section 12.00" target="_blank">12.00</a>.
</li>
          </ol>
      <p></p>
      <!--<p align="left"> Appropriate hematologic evidence
                  for sickle cell disease, such as hemoglobin electrophoresis, must
                  be included. Vaso-occlusive or aplastic episodes should be documented
                  by description of severity, frequency, and duration. </p>
                <p align="left" > Major visceral episodes include
                  meningitis, osteomyelitis, pulmonary infections or infarctions,
                  cerebrovascular accidents, congestive heart failure, genito-urinary
                  involvement, etc. </p> -->
      <p align="left" id="7_00D">
          D. <u>What are disorders of thrombosis and hemostasis, and how do we evaluate them under <a href="#7_08" title="Section 7.08">7.08</a>?</u>
          </p><ol>
              <li id="7_00D1">
                  <u>Disorders of thrombosis and hemostasis</u> include both clotting and bleeding disorders, and may be congenital or acquired. These disorders are characterized by abnormalities in blood clotting that result in hypercoagulation (excessive blood clotting) or hypocoagulation (inadequate blood clotting). The diagnosis of a thrombosis or hemostasis disorder is based on evaluation of plasma clotting-factor proteins (factors) and platelets. Protein C or protein S deficiency and Factor V Leiden are examples of hypercoagulation disorders. Hemophilia, von Willebrand disease, and thrombocytopenia are examples of
                  hypocoagulation disorders. Acquired excessive blood clotting may result from blood protein defects and acquired inadequate blood clotting (for example, acquired
                  hemophilia A) may be associated with inhibitor autoantibodies.
              </li>
              <br>
              <li id="7_00D2">
                   The hospitalizations in <a href="#7_08" title="Section 7.08">
                    7.08</a> do not all have to be for the same complication
                    of a disorder of thrombosis and hemostasis. They may be for three different
                    complications of the disorder. Examples of complications that may result in
                    hospitalization include anemias, thromboses, embolisms, and uncontrolled bleeding
                    requiring multiple factor concentrate infusions or platelet transfusions. We will
                    also consider any surgery that you have, even if it is not related to your hematological
                    disorder, to be a complication of your disorder of thrombosis and hemostasis if
                    you require treatment with clotting-factor proteins
                    (for example, factor VIII or factor IX) or anticoagulant medication to control
                    bleeding or coagulation in connection with your surgery. We will count the hours
                    you receive emergency treatment in a comprehensive hemophilia treatment center
                    immediately before the hospitalization if this treatment is comparable to the
                    treatment provided in a hospital emergency department.
              </li>
          </ol>
      <p></p>
      <p align="left" id="7_00E">
          
          E. <u>What are disorders of bone marrow failure, and how do we evaluate them under <a href="#7_10" title="Section 7.10">7.10</a>?</u>
          </p><ol>
              <li id="7_00E1">
                  
                  <u>Disorders of bone marrow failure</u> may be congenital or acquired, characterized
                  by bone marrow that does not make enough healthy RBCs, platelets, or granulocytes
                  (specialized types of white blood cells); there may also be a combined failure of
                  these bone marrow-produced cells. The diagnosis is based on peripheral blood smears
                  and bone marrow aspiration or bone marrow biopsy, but not peripheral blood smears
                  alone. Examples of these disorders are myelodysplastic syndromes, aplastic anemia,
                  granulocytopenia, and myelofibrosis. Acquired disorders of bone marrow failure may
                  result from viral infections, chemical exposure, or immunologic disorders.
              </li>
              <br>
              <li id="7_00E2">
                  
                  The hospitalizations in <a href="#7_10A" title="Section 7.10">7.10A</a> do not all have to be for the same complication
                    of bone marrow failure. They may be for three different complications of the disorder.
                    Examples of complications that may result in hospitalization include uncontrolled
                    bleeding, anemia, and systemic bacterial, viral, or fungal infections.
              </li>
              <br>
              <li id="7_00E3">
                  
                  For <a href="#7_10B" title="Section 7.10B">7.10B</a>, the requirement of life-long RBC transfusions to maintain life in
                myelodysplastic syndromes or aplastic anemias has the same meaning as it does
                for beta thalassemia major (see <a href="#7_00C4" title="Section 7.00, Subsection C4">7.00C4</a>).
            </li>
          </ol>
      <p></p>
      <p align="left" id="7_00F">
          
          F. <u>How do we evaluate bone marrow or stem cell transplantation under <a href="#7_17" title="Section 7.17">7.17</a>?</u> We will consider you to be disabled for 12 months from the date of bone
          marrow or stem cell transplantation, or we may consider you to be disabled for a longer period if you are experiencing any serious post-transplantation complications, such as graft-versus-host (GVH) disease, frequent infections
          after immunosuppressive therapy, or significant deterioration of organ systems. We do not restrict our determination of the onset of disability to the date of
          the transplantation in <a href="#7_17" title="Section 7.17">7.17</a>. We may establish an earlier onset date of disability due to your transplantation if evidence in your case record
    supports such a finding.
</p>
      <p align="left" id="7_00G">
          
          G. <u>How do we use the functional criteria in <a href="#7_18" title="Section 7.18">7.18</a>?</u>
          </p><ol>
              <li id="7_00G1">
                    When we use the functional criteria in <a href="#7_18" title="Section 7.18">7.18</a>, we consider all relevant
                    information in your case record to determine the impact of your hematological
                    disorder on your ability to function independently, appropriately, effectively,
                    and on a sustained basis in a work setting. Factors we will consider when we
                    evaluate your functioning under <a href="#7_18" title="Section 7.18">7.18</a> include, but are not limited to: your
                    symptoms, the frequency and duration of complications of your hematological
                    disorder, periods of exacerbation and remission, and the functional impact of
                    your treatment, including the side effects of your medication.
              </li>
              <br>
              <li id="7_00G2">
                  <u>Repeated complications</u> means that the complications occur on an average of three times a year, or once every 4 months, each lasting 2 weeks or more;
                  or the complications do not last for 2 weeks but occur substantially more frequently than three times in a year or once every 4 months; or they occur less frequently than an average of three times a year or once every 4 months
                  but last substantially longer than 2 weeks. Your impairment will satisfy this criterion regardless of whether you have the same kind of complication repeatedly, all different complications, or any other combination of complications; for example, two of the same kind of complication and a
                  different one. You must have the required number of complications with the frequency and duration required in this section. Additionally, the complications must occur within the period we are considering in connection
                  with your application or continuing disability review.
              </li>
              <br>
              <li id="7_00G3">
                  To satisfy the functional criteria in <a href="#7_18" title="Section 7.18">7.18</a>, 
                  your hematological disorder must result in a "marked" level of limitation in one of three general areas of functioning: 
                  activities of daily living, social functioning, or difficulties in completing tasks due to deficiencies in concentration, persistence, or pace. 
                  Functional limitations may result from the impact of the disease process itself on your mental functioning, physical functioning, or both your mental and physical functioning. 
                  This limitation could result from persistent or intermittent symptoms, such as pain, severe fatigue, or malaise, resulting in a limitation of your ability to do a task, to concentrate, to persevere at a task, 
                  or to perform the task at an acceptable rate of speed. (<u>Severe fatigue</u> means a frequent sense of exhaustion that results in significant reduced physical activity 
                  or mental function. <u>Malaise</u> means frequent feelings of illness, bodily discomfort, or lack of well-being that result in significantly reduced physical activity or mental function.) 
                  You may also have limitations because of your treatment and its side effects.
</li>
              <br>
              <li id="7_00G4">
                  <u>Marked</u> limitation means that the symptoms and signs of your hematological disorder interfere <u>seriously</u> with your ability to function. Although we do not require the use of such a scale, "marked" would be the fourth point on a
                  five-point scale consisting of no limitation, mild limitation, moderate limitation, marked limitation, and extreme limitation. We do not define "marked" by a specific number of different activities of daily living or
                  different behaviors in which your social functioning is impaired, or a specific number of tasks that you are able to complete, but by the nature and overall degree of interference with your functioning. You may have a marked limitation when several activities or functions are impaired, or even when only one is impaired. Additionally, you need not be totally precluded from performing an activity to have a marked limitation, as long
                  as the degree of limitation interferes seriously with your ability to function independently, appropriately, and effectively. The term "marked" does not imply
                  that you must be confined to bed, hospitalized, or in a nursing home.
              </li>
              <br>
              <li id="7_00G5">
                  <u>Activities of daily living</u> include, but are not limited to, such activities as doing household chores, grooming and hygiene, using a post office, taking public transportation, or paying bills. We will find that
                  you have a "marked" limitation in activities of daily living if you have a serious limitation in your ability to maintain a household or take public transportation because of symptoms such as pain, severe fatigue, anxiety, or difficulty concentrating, caused by your hematological
                  disorder (including complications of the disorder) or its treatment, even if you are able to perform some self-care activities.
              </li>
              <br>
              <li id="7_00G6">
                  <u>Social functioning</u> includes the capacity to interact with others independently, appropriately, effectively, and on a sustained basis. It includes the ability to communicate effectively with others. We will find that you have a "marked" limitation in maintaining social functioning if you have a serious limitation in social interaction on
                  a sustained basis because of symptoms such as pain, severe fatigue, anxiety, or difficulty concentrating, or a pattern of exacerbation and remission, caused by your hematological disorder (including complications of the disorder) or its treatment, even if you are able to communicate with close friends or relatives.
              </li>
              <br>
              <li id="7_00G7">
                  <u>Completing tasks in a timely manner</u> involves the ability to sustain concentration, persistence, or pace to permit timely completion of tasks commonly found in work settings. We will find that you have a "marked" limitation in completing tasks if you have a serious limitation in your
                  ability to sustain concentration or pace adequate to complete work-related tasks because of symptoms, such as pain, severe fatigue, anxiety, or difficulty concentrating caused by your hematological disorder
                  (including complications of the disorder) or its treatment, even if you are able to do some routine activities of daily living.
              </li>
          </ol>
      <p></p>
      <p align="left" id="7_00H">
          
          H. <u>How do we consider your symptoms, including your pain, severe fatigue, and malaise?</u> Your symptoms, including pain, severe fatigue, and malaise, may be important factors in our determination whether your hematological
          disorder(s) meets or medically equals a listing, or in our determination whether you are otherwise able to work. We  cannot consider your symptoms unless you have medical signs or laboratory findings showing the existence of a medically determinable impairment(s) that could reasonably be
          expected to produce the symptoms. If you have such an impairment(s), we will evaluate the intensity, persistence, 
          and functional effects of your symptoms using the rules throughout <a href="#7_00" title="Section 7.00">7.00</a> and in our other regulations.
    (See  sections <a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1521.htm" target="_blank" title="Code of Federal Regulations section 404.1521">404.1521</a>,
    <a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1529.htm" target="_blank" title="Code of Federal Regulations section 404.1529">404.1529</a>,
    <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0921.htm" target="_blank" title="Code of Federal Regulations section 416.921">416.921</a>, and
    <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0929.htm" target="_blank" title="Code of Federal Regulations section 416.929">416.929</a> of this chapter)
    Additionally, when we assess the credibility of your complaints about your symptoms and their functional effects, we will not draw any inferences from the fact that you do not receive treatment or that
    you are not following treatment without considering all of the relevant evidence in your case record, including any explanations you
    provide that may explain why you are not receiving or following treatment.
</p>
      <p align="left" id="7_00I">
          
          I. <u>How do we evaluate episodic events in hematological disorders? </u>Some of the listings in this body system require a specific number of events within a consecutive 12-month period. 
          (See <a href="#7_05" title="Section 7.05">7.05</a>, <a href="#7_08" title="Section 7.08">7.08</a>, and <a href="#7_10A" title="Section 7.10, Subsection A">7.10A</a>.) When we use such criteria, a consecutive 12-month period means a
    period of 12 consecutive months, all or part of which must occur within the period we are considering in connection with your application or continuing disability review. These events must occur at least 30 days apart to ensure that we are evaluating separate events.
</p>
      <p align="left" id="7_00J">
          
          J. <u>How do we evaluate hematological disorders that do not meet one of these listings?</u></p>
          <ol>
              <li id="7_00J1">
                  These listings are only common examples of hematological disorders that we consider severe enough to prevent a person from doing any gainful activity. If your disorder does not meet the criteria of any of these listings, we must consider whether you have a disorder that satisfies the criteria of a listing in another body system. For example, we will evaluate hemophilic joint deformity or bone or
                  joint pain from myelofibrosis under <a href="1.00-Musculoskeletal-Adult.htm#1_00" title="1.00 Musculoskeletal System Page, Section 1.00" target="_blank">1.00</a>;
    polycythemia vera under <a href="3.00-Respiratory-Adult.htm#3_00" title="3.00 Respiratory Disorders Page, Section 3.00" target="_blank">3.00</a>, 
              <a href="4.00-Cardiovascular-Adult.htm#4_00" title="4.00 Cardiovascular System Page, Section 4.00" target="_blank">4.00</a>,
    or <a href="11.00-Neurological-Adult.htm#11_00" title="11.00 Neurological Disorders Page, Section 11.00" target="_blank">11.00</a>; chronic iron overload resulting from repeated RBC transfusion (transfusion hemosiderosis) under
       <a href="3.00-Respiratory-Adult.htm#3_00" title="3.00 Respiratory Disorders Page, Section 3.00" target="_blank">3.00</a>, 
              <a href="4.00-Cardiovascular-Adult.htm#4_00" title="4.00 Cardiovascular System Page, Section 4.00" target="_blank">4.00</a>, 
              or <a href="5.00-Digestive-Adult.htm#5_00" title="5.00 Digestive System Page, Section 5.00" target="_blank">5.00</a>;
            and the effects of intracranial bleeding or stroke under <a href="11.00-Neurological-Adult.htm#11_00" title="11.00 Neurological Disorders Page, Section 11.00" target="_blank">11.00</a> or 
              <a href="12.00-MentalDisorders-Adult.htm#12_00" title="12.00 Neurological Disorders Page, Section 12.00" target="_blank">12.00</a>.
</li>
              <br>
              <li id="7_00J2">
                  If you have a severe medically determinable impairment(s) that does not meet a listing, we will determine whether your impairment(s) medically equals a listing. 
              (See sections <a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1526.htm" target="_blank" title="Code of Federal Regulations section 404.1526">404.1526</a> and 
                            <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0926.htm" target="_blank" title="Code of Federal Regulations section 416.926">416.926</a> of this chapter.) 
                                Hematological disorders may be associated with disorders in other body systems,
                                and we consider the combined effects of multiple impairments when we determine whether they medically equal a listing.
                                If your impairment(s) does not medically equal a listing, you may or may not have the residual functional capacity to engage in substantial gainful activity.
                                We proceed to the fourth, and, if necessary, the fifth steps of the sequential evaluation process in sections
                                <a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1520.htm" target="_blank" title="Code of Federal Regulations section 404.1520">404.1520</a> and
                                <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0920.htm" target="_blank" title="Code of Federal Regulations section 416.920">416.920</a>.
                                We use the rules in sections <a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1594.htm" target="_blank" title="Code of Federal Regulations section 404.1594">404.1594</a>,
                                <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0994.htm" target="_blank" title="Code of Federal Regulations section 416.994">416.994</a>,
                                and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0994a.htm" target="_blank" title="Code of Federal Regulations section 416.994, Subsection a">416.994a</a> of this chapter, as appropriate,
                                when we decide whether you continue to be disabled.
</li>
          </ol>
      <p align="left">&nbsp; </p>
      <p><b><a href="#Top" class="seventypercent">Back to Top</a></b></p>
      <p align="left" id="7_01">
          <b>
              
              7.01 Category of Impairments,  <strong> Hematological Disorders</strong>
          </b>
      </p>
      <!--
    <p align="left" ><b>
                <a name="7_02" id="7_02"></a>
                  7.02 <i>Chronic anemia(hematocrit persisting</i> </b>
                  <i> at 30 percent or less due to any cause) </i>With: </p>
                <p align="left" > A. Requirement of one or more
                  blood transfusions on an average of at least once every 2 months;
                  or </p>
                <p align="left" > B. Evaluation of the resulting
                  impairment under criteria for the affected body system. </p> -->
      <p align="left" id="7_05">
          <b>
              
              7.05 <i>Hemolytic anemias,</i>
          </b> including sickle cell disease, thalassemia, and their variants (see <a href="#7_00C" title="Section 7.00, Subsection C">7.00C</a>), <i></i>with:
    </p><ol type="A">
        <li id="7_05A">Documented painful (vaso-occlusive) crises requiring parenteral (intravenous or intramuscular) narcotic medication, occurring at least six times within a 12-month period with at least 30 days between crises.</li>
        <br>
        OR
        <br>
        <br>
        <li id="7_05B">
            
            Complications of hemolytic anemia requiring at least  three hospitalizations within a 12-month period and occurring at least 30 days apart. 
            Each hospitalization must last at least 48 hours, which can include hours in a hospital emergency department or comprehensive sickle cell disease center immediately before
            the hospitalization (see <a href="#7_00C2" title="Section 7.00, Subsection C2">7.00C2</a>)
</li>
        <br>
        OR
        <br>
        <br>
        <li id="7_05C">Hemoglobin measurements of 7.0 grams per deciliter (g/dL) or less, occurring at least three times within a 12-month period with at least 30 days between measurements.</li>
        <br>
        OR
        <br>
        <br>
        <li id="7_05D">
            
            Beta thalassemia major requiring life-long RBC transfusions at
            least once every 6 weeks to maintain life (see <a href="#7_00C4" title="Section 7.00, Subsection C4">7.00C4</a>).
</li>
    </ol>
<p></p>
      <!--<p align="left"> <b><a name="7_06" id="7_06"></a>
      7.06 <i>Chronic thrombocytopenia (due to any cause)</i></b><i>,
      </i>with platelet counts repeatedly below 40,000/ cubic millimeter.
      With:
    <p align="left"> A. At least one spontaneous
      hemorrhage, requiring transfusion, within 5 months prior to adjudication;
      or </p>
    <p align="left">B. Intracranial bleeding
      within 12 months prior to adjudication.</p> -->
      <!--<p align="left" ><b><a name="7_07" id="7_07"></a>
      7.07 <i>Hereditary telangiectasia</i></b> with hemorrhage requiring
      transfusion at least three times during the 5 months prior to adjudication.            </p>
    <p align="left" ><b> -->
      <p id="7_08"><b>
          7.08 <i>Disorders of thrombosis and hemostasis</i>
      </b>, including hemophilia and thrombocytopenia (see <a href="#7_00D" title="Section 7.00, Subsection D">7.00D</a>), with complications requiring at least
    three hospitalizations within a 12<i> </i>month period and occurring at least 30 days apart prior to adjudication. Each hospitalization must
    last at least 48 hours, which can include hours in the hospital emergency
    department or comprehensive hemophilia treatment center immediately before
    the hospitalization (see <a href="#7_00D2" title="Section 7.00, Subsection D2">7.00D2</a>). </p>
    <!--<p align="left"><b>
    <a name="7_09" id="7_09"></a>
      7.09 </b> <i> <b>
      Polycythemia vera (with erythrocytosis, splenomegaly, and leukocytosis
      or thrombocytosis)</b>. </i>Evaluate the resulting impairment
      under the criteria for the affected body system. </p> -->
    <p align="left" id="7_10">
        <b>
            7.10 <i>Disorders of bone marrow failure,</i>
        </b> including myelodysplastic syndromes, aplastic anemia, granulocytopenia, and myelofibrosis (see <a href="#7_00E" title="Section 7.00, Subsection E">7.00E</a>), with:</p>
    <ol type="A">
        <li id="7_10A">
            Complications of bone marrow failure requiring at least
            three hospitalizations within a 12-month period and
            occurring at least 30 days apart. Each hospitalization
            must last at least 48 hours, which can include hours in
            a hospital emergency department immediately before the
            hospitalization (see <a href="#7_00E2" title="Section 7.00, Subsection E2">7.00E2</a>).
</li>
        <br>
        OR
        <br>
        <br>
        <li id="7_10B">
            Myelodysplastic syndromes or aplastic anemias requiring
            life-long RBC transfusions at least once every 6 weeks
            to maintain life (see <a href="#7_00E3" title="Section 7.00, Subsection E3">7.00E3</a>).
</li>
    </ol>
    <!--<p align="left">C. Intractable bone pain
                with radiologic evidence of osteosclerosis. </p> -->
<p>
        <b>
            <a href="#Top" class="seventypercent">
                Back
                to Top
            </a>
        </b>
    </p>
    <!--<p align="left" ><b> </b><b>
    <a name="7_15" id="7_15"></a>
      7.15 </b> <i><b>Chronic
       granulocytopenia (due to any cause)</b>. </i>With both A and
      B: </p>
    <p align="left">A. Absolute neutrophil
      counts repeatedly below 1,000 cells/cubic millimeter; and </p>
    <p align="left"> B. Documented recurrent
        systemic bacterial infections occurring at least 3 times during
      the 5 months prior to </p> -->
    <p align="left" id="7_17">
        <b>
            7.17 <i>Hematological disorders treated by bone marrow or stem cell transplantation (see <a href="#7_00F" title="Section 7.00, Subsection F">7.00F</a>) </i>
        </b><i>
            .
        </i>Consider under a disability for at least 12 consecutive months from the date of transplantation.
        After that, evaluate any residual impairment(s) under the criteria for the affected body system.
    </p>
    <p align="left" id="7_18">
        <b>
            7.18 <i>Repeated complications of hematological disorders (see <a href="#7_00G2" title="Section 7.00, Subsection G2">7.00G2</a>)</i>
        </b> including those complications listed in <a href="#7_05" title="Section 7.05">7.05</a>, <a href="#7_08" title="Section 7.08">7.08</a>,
    and <a href="#7_10" title="Section 7.10">7.10</a> but without the requisite findings for those
    listings, or other complications (for example, anemia,
    osteonecrosis, retinopathy, skin ulcers, silent central
    nervous system infarction, cognitive or other mental
    limitation, or limitation of joint movement), resulting
    in significant, documented symptoms or signs (for example,
    pain, severe fatigue, malaise, fever, night sweats,
    headaches, joint or muscle swelling, or shortness of
    breath), and one of the following at the marked level (see <a href="#7_00G4" title="Section 7.00, Subsection G4">7.00G4</a>)
    </p><ol type="A">
        <li id="7_18A"> Limitation of activities of daily living (see <a href="#7_00G5" title="Section 7.00, Subsection G5">7.00G5</a>).</li>
        <br>
        <li id="7_18B">Limitation in maintaining social functioning (see <a href="#7_00G6" title="Section 7.00, Subsection G6">7.00G6</a>).</li>
        <br>
        <li id="7_18C">Limitation in completing tasks in a timely manner due to deficiencies in concentration, persistence, or pace (see <a href="#7_00G7" title="Section 7.00, Subsection G7">7.00G7</a>).</li>
	</ol>
<p></p>
    <p>
        <b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b>
    </p>
    
 </article><!-- END SECOND INNER COLUMN -->
 
 </div><!-- END GRID-->

</article><!-- END SECOND COLUMN -->

</div><!-- END GRID-->

    </section>
  </main>
  <!-- FOOTER -->
  <ssa-footer class="print-dn"></ssa-footer><script src="https://www.ssa.gov/legacy/components/dist/ssa-footer.js"></script>
  <!-- SCRIPTS -->
  <script src="/framework/js/ssa.firefly.body.js"></script><a class="js-btt" href="#" title="Back to Top"></a>


</body></html>